Matrix metalloproteinases: Drug targets for myocardial infarction

Current Drug Targets

Volumn 14, Issue 3, 2013, Pages 276-286

  Yabluchanskiy, Andriy ^a,b   Li, Yaojun ^a,b   Chilton, Robert J ^a,b   Lindsey, Merry L ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Extracellular matrix; Left ventricle; Left ventricle remodeling; Matrix metalloproteinases; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALTEPLASE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; COLLAGENASE 3; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; DOXYCYCLINE HYCLATE; FIBRINOLYTIC AGENT; FIBRONECTIN; GELATINASE A; GELATINASE B; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERSTITIAL COLLAGENASE; LAMININ; LISINOPRIL; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PLASMINOGEN ACTIVATOR; PROTEOGLYCAN; SPIRONOLACTONE; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE; UNINDEXED DRUG;

ARTHRITIS; CELL DEATH; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; CLINICAL RESEARCH; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIA; MACROPHAGE; MYOFIBROBLAST; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTOSIS; REPERFUSION; REVIEW; ST SEGMENT ELEVATION; TISSUE INJURY; VASCULITIS; WOUND HEALING;

EID: 84876739431     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945013804999007     Document Type: Review

References (152)

1. Hein S, Schaper J. The extracellular matrix in normal and diseased myocardium. Journal of nuclear cardiology: official publication of the American Society of Nuclear Cardiology 2001; 8(2): 188-96.
2. Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ. Matrix metalloproteinases in peripheral vascular disease. Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 2007; 45(4): 849-57.
3. Pelouch V, Dixon IM, Golfman L, Beamish RE, Dhalla NS. Role of extracellular matrix proteins in heart function. Mol Cell Biochem 1993; 129(2): 101-20.
4. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. Faseb J 1997; 11(1): 51-9.
5. Lindsey ML, Borg TK. Understanding the role of the extracellular matrix in cardiovascular development and disease: where do we go from here? J mol cell cardiol 2010; 48(3): 431-2.
6. Liu P, Sun M, Sader S. Matrix metalloproteinases in cardiovascular disease. Can J Cardiol 2006; 22 Suppl B: 25B-30B.
7. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101(25): 2981-8.
8. Phatharajaree W, Phrommintikul A, Chattipakorn N. Matrix metalloproteinases and myocardial infarction. Can J Cardiol 2007; 23(9): 727-33.
9. Vu DT, Martinez EC, Kofidis T. Myocardial restoration: is it the cell or the architecture or both? Cardiol Res Pract 2012; 2012: 240497.
10. Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996; 74(1): 86-107.
11. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol 1994; 34: 17-40.
12. Distelmaier K, Adlbrecht C, Jakowitsch J, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009; 102(3): 564-72.
13. Zuidema MY, Zhang C. Ischemia/reperfusion injury: The role of immune cells. World J Cardiol 2010; 2(10): 325-32.
14. Kempf T, Zarbock A, Vestweber D, Wollert KC. Antiinflammatory mechanisms and therapeutic opportunities in myocardial infarct healing. J Mol Med (Berl) 2012; 90(4): 361-9.
15. Di Filippo C, Rossi F, D'Amico M. Targeting polymorphonuclear leukocytes in acute myocardial infarction. ScientificWorldJournal 2007; 7: 121-34.
16. Lindsey ML, Zamilpa R. Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovasc Ther 2012; 30(1): 31-41.
17. Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 2002; 54(3): 549-58.
18. Deten A, Volz HC, Holzl A, Briest W, Zimmer H-G. Effect of propranolol on cardiac cytokine expression after myocardial infarction in rats. Mol Cell Biochem 2003; 251(1-2): 127-37.
19. Lindsey M, Wedin K, Brown MD, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001; 103(17): 2181-7.
20. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int J Cardiol 2008; 130(2): 147-58.
21. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999; 341(10): 738-46.
22. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002; 111(5): 635-46.
23. Ma Y, Chiao YA, Zhang J, Manicone AM, Jin YF, Lindsey ML. Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal 2012; 18(1): 81-90
24. Moldovan NI, Goldschmidt-Clermont PJ, Parker-Thornburg J, Shapiro SD, Kolattukudy PE. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res 2000; 87(5): 378-84.
25. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994; 55(3): 410-22.
26. West DC, Kumar S. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res 1989; 183(1): 179-96.
27. Demirdogen B, Elcin AE, Elcin YM. Neovascularization by bFGF releasing hyaluronic acid-gelatin microspheres: in vitro and in vivo studies. Growth Factors 2010; 28(6): 426-36.
28. Bauer AL, Jackson TL, Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol 2009; 5(7): e1000445.
29. Arroyo AG, Iruela-Arispe ML. Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc Res 2010; 86(2): 226-35.
30. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170(6): 1807-16.
31. Yano T, Miura T, Whittaker P, et al. Macrophage colonystimulating factor treatment after myocardial infarction attenuates left ventricular dysfunction by accelerating infarct repair. J Am Coll Cardiol 2006; 47(3): 626-34.
32. Riches K, Morley ME, Turner NA, et al. Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts. J Mol Cell Cardiol 2009; 47(3): 391-9.
33. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009; 123(2): 255-78.
34. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005; 288(2): H461-8.
35. Lijnen P, Petrov V, Fagard R. Transforming growth factor-beta 1-mediated collagen gel contraction by cardiac fibroblasts. J Renin Angiotensin Aldosterone Syst 2003; 4(2): 113-8.
36. Ma F, Li Y, Jia L, et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. PloS one 2012; 7(5): e35144.
37. Turner NA, Das A, Warburton P, O'Regan DJ, Ball SG, Porter KE. Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. Am J Physiol Heart Circ Physiol 2009; 297(3): H1117-27.
38. Zhan S, Chan CC, Serdar B, Rockey DC. Fibronectin stimulates endothelin-1 synthesis in rat hepatic myofibroblasts via a Src/ERKregulated signaling pathway. Gastroenterology 2009; 136(7): 2345-55 e1-4.
39. Tummalapalli CM, Heath BJ, Tyagi SC. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem 2001; 80(4): 512-21.
40. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012; 92(2): 635-88.
41. Dutta D, Calvani R, Bernabei R, Leeuwenburgh C, Marzetti E. Contribution of impaired mitochondrial autophagy to cardiac aging: mechanisms and therapeutic opportunities. Circ Res 2012; 110(8): 1125-38.
42. Lindsey ML, Mann DL, Entman ML, Spinale FG. Extracellular matrix remodeling following myocardial injury. Ann Med 2003; 35(5): 316-26.
43. Spinale FG. Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function. Physiol Rev 2007; 87(4): 1285-342.
44. Mieke MHvM. Matrix Metalloproteinases and Collagen Remodeling. BMTE 2006.
45. Medugorac I. Characterization of intramuscular collagen in mammalian left ventricle. Basic Res Cardiol 1982; 77(6): 589-98.
46. Kanzaki Y, Yamauchi Y, Okabe M, Terasaki F, Ishizaka N. Threedimensional architecture of cardiomyocytes and connective tissues in hypertrophic cardiomyopathy: a scanning electron microscopic observation. Circulation 2012; 125(5): 738-9.
47. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. AnnuRevBiochem 1995; 64: 403-34.
48. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. AmJPathol 1995; 147(2): 325-38.
49. Wei S, Chow LT, Shum IO, Qin L, Sanderson JE. Left and right ventricular collagen type I/III ratios and remodeling postmyocardial infarction. J Card Fail 1999; 5(2): 117-26.
50. Zimmerman SD, Thomas DP, Velleman SG, Li X, Hansen TR, McCormick RJ. Time course of collagen and decorin changes in rat cardiac and skeletal muscle post-MI. Am J Physiol Heart Circ Physiol 2001; 281(4): H1816-22.
51. Solomon SD, Pfeffer MA. Renin-angiotensin system and cardiac rupture after myocardial infarction. Circulation 2002; 106(17): 2167-9.
52. Sane DC, Mozingo WS, Becker RC. Cardiac rupture after myocardial infarction: new insights from murine models. Cardiol Rev 2009; 17(6): 293-9.
53. Fraccarollo D, Galuppo P, Bauersachs J, Ertl G. Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res 2002; 54(3): 559-67.
54. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106(1): 55-62.
55. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996; 179(3): 321-5.
56. van Dijk A, Niessen HW, Ursem W, Twisk JW, Visser FC, van Milligen FJ. Accumulation of fibronectin in the heart after myocardial infarction: a putative stimulator of adhesion and proliferation of adipose-derived stem cells. Cell Tissue Res 2008; 332(2): 289-98.
57. Ulrich MM, Janssen AM, Daemen MJ, et al. Increased expression of fibronectin isoforms after myocardial infarction in rats. J Mol Cell Cardiol 1997; 29(9): 2533-43.
58. Mosher DF. A role for fibronectin in self-repair after ischemic injury. Nature medicine 2001; 7(3): 290-2.
59. Santiago JJ, Dangerfield AL, Rattan SG, et al. Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn 2010; 239(6): 1573-84.
60. Trial J, Rossen RD, Rubio J, Knowlton AA. Inflammation and ischemia: macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes. Exp Biol Med (Maywood) 2004; 229(6): 538-45.
61. Zamilpa R, Lopez EF, Chiao YA, et al. Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics 2010; 10(11): 2214-23.
62. Chiao YA, Zamilpa R, Lopez EF, et al. In vivo matrix metalloproteinase-7 substrates identified in the left ventricle postmyocardial infarction using proteomics. J Proteome Res 2010; 9(5): 2649-57.
63. Gronthos S, Simmons PJ, Graves SE, Robey PG. Integrin-mediated interactions between human bone marrow stromal precursor cells and the extracellular matrix. Bone 2001; 28(2): 174-81.
64. Gu Z, Cui J, Brown S, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005; 25(27): 6401-8.
65. Dinh W, Bansemir L, Futh R, et al. Increased levels of laminin and collagen type VI may reflect early remodelling in patients with acute myocardial infarction. Acta Cardiol 2009; 64(3): 329-34.
66. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003; 34(9): 2165-70.
67. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 2005; 115(3): 599-609.
68. van Dijk A, Niessen HW, Zandieh Doulabi B, Visser FC, van Milligen FJ. Differentiation of human adipose-derived stem cells towards cardiomyocytes is facilitated by laminin. Cell Tissue Res 2008; 334(3): 457-67.
69. Harris BS, Zhang Y, Card L, Rivera LB, Brekken RA, Bradshaw AD. SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. Am J Physiol Heart Circ Physiol 2011; 301(3): H841-7.
70. McCurdy SM, Dai Q, Zhang J, et al. SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 2011; 301(2): H497-505.
71. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol 2000; 19(7): 569-80.
72. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107(9): 1049-54.
73. Schellings MW, Vanhoutte D, Swinnen M, et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med 2009; 206(1): 113-23.
74. McClung HM, Thomas SL, Osenkowski P, et al. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett 2007; 419(2): 172-7.
75. Sezaki S, Hirohata S, Iwabu A, et al. Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion. Exp Biol Med (Maywood) 2005; 230(9): 621-30.
76. Chatila K, Ren G, Xia Y, Huebener P, Bujak M, Frangogiannis NG. The role of the thrombospondins in healing myocardial infarcts. Cardiovasc Hematol Agents Med Chem 2007; 5(1): 21-7.
77. Scott JE. Proteoglycan-fibrillar collagen interactions. Biochem J 1988; 252(2): 313-23.
78. Cavalcante FSA, Ito S, Brewer K, et al. Mechanical interactions between collagen and proteoglycans: implications for the stability of lung tissue. J Appl Physiol 2005; 98(2): 672-9.
79. Campbell PH, Hunt DL, Jones Y, Harwood F, Amiel D, Omens JH, et al. Effects of biglycan deficiency on myocardial infarct structure and mechanics. Mol Cell Biomech 2008; 5(1): 27-35.
80. Takemoto S, Murakami T, Kusachi S, et al. Increased expression of dermatopontin mRNA in the infarct zone of experimentally induced myocardial infarction in rats: comparison with decorin and type I collagen mRNAs. Basic Res Cardiol 2002; 97(6): 461-8.
81. Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature medicine 1996; 2(4): 418-23.
82. Li J, Brown LF, Laham RJ, Volk R, Simons M. Macrophagedependent regulation of syndecan gene expression. Circ Res 1997; 81(5): 785-96.
83. Matsui Y, Ikesue M, Danzaki K, et al. Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ Res 2011; 108(11): 1328-39.
84. Cleutjens JPM, Blankesteijn WM, Daemen MJAP, Smits JFM. The infarcted myocardium: Simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 1999; 44(2): 232-41.
85. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 2002; 40(1): 43-8.
86. Kelly D, Khan S, Cockerill G, et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 2008; 10(2): 133-9.
87. Lindsey ML, Escobar GP, Mukherjee R, et al. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 2006; 113(25): 2919-28.
88. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nature reviews Cardiology 2010; 7(1): 30-7.
89. Hodgson J. Remodeling MMPIs. Biotechnology (N Y) 1995; 13(6): 554-7.
90. Bachmann LH, Stephens J, Richey CM, Hook EW, 3rd. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis 1999; 26(5): 272-8.
91. Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003; 48(6): 1742-9.
92. Skiles JW, Gonnella NC, Jeng AY. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 2001; 8(4): 425-74.
93. Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. (Chem. Rev. 1999, 99, 2735-2776. Published on the web september 8, 1999). Chem Rev 2001; 101(7): 2205-6.
94. Kontogiorgis CA, Papaioannou P, Hadjipavlou-Litina DJ. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. Curr Med Chem 2005; 12(3): 339-55.
95. Sarkhel S, Desiraju GR. N-H. O, O-H. O, and C-H. O hydrogen bonds in protein-ligand complexes: strong and weak interactions in molecular recognition. Proteins 2004; 54(2): 247-59.
96. Makitalo L, Kolho KL, Karikoski R, Anthoni H, Saarialho-Kere U. Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scand J Gastroenterol 2010; 45(7-8): 862-71.
97. Kim DH, Mobashery S. Mechanism-based inhibition of zinc proteases. Curr Med Chem 2001; 8(8): 959-65.
98. Kleifeld O, Kotra LP, Gervasi DC, et al. X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme. J Biol Chem 2001; 276(20): 17125-31.
99. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9(1): 63-79.
100. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33(3): 831-6.
101. Tziakas DN, Chalikias GK, Parissis JT, et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 2004; 94(2-3): 269-77.
102. Heo JH, Kim SH, Lee KY, Kim EH, Chu CK, Nam JM. Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 2003; 34(6): e48-50.
103. Nutescu EA, Shapiro NL, Chevalier A, Amin AN. A pharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med 2005; 72 Suppl 1: S2-6.
104. Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Cardiol Clin 2008; 26(2): 169-87, v-vi.
105. Rababah M, Worthmann H, Deb M, et al. Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls. Clin Biochem 2012; 45(6): 483-9.
106. Castellazzi M, Tamborino C, Fainardi E, et al. Effects of anticoagulants on the activity of gelatinases. Clin Biochem 2007; 40(16-17): 1272-6.
107. Mannello F, Jung K, Tonti GA, Canestrari F. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem 2008; 41(18): 1466-73.
108. Pfeffer MA. ACE inhibitors in acute myocardial infarction: patient selection and timing. Circulation. 1998; 97(22): 2192-4.
109. Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Curr Med Chem 2009; 16(11): 1349-54.
110. Yamamoto D, Takai S, Miyazaki M. Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochem Biophys Res Commun 2007; 354(4): 981-4.
111. Yamamoto D, Takai S, Miyazaki M. Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol 2008; 588(2-3): 277-9.
112. Miyazaki S, Kasai T, Miyauchi K, et al. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. Circ J 2010; 74(6): 1158-64.
113. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999; 100(20): 2093-9.
114. Cipollone F, Fazia M, Iezzi A, et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 109(12): 1482-8.
115. Brassard P, Amiri F, Schiffrin EL. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension 2005; 46(3): 598-606.
116. Yamashita C, Hayashi T, Mori T, et al. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 2007; 30(12): 1219-30.
117. Yang D, Ma S, Li D, Tang B, Yang Y. Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium. Biochem Biophys Res Commun 2009; 388(3): 606-11.
118. Excellence NIfHaC. Prophylaxis for patients who have experienced a myocardial infarction 2011.
119. Rude MK, Duhaney T-AS, Kuster GM, et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 2005; 46(3): 555-61.
120. Mill JG, Milanez Mda C, de Resende MM, Gomes Mda G, Leite CM. Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. Clin Exp Pharmacol Physiol 2003; 30(10): 739-44.
121. Ceron CS, Castro MM, Rizzi E, et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010; 160(1): 77-87.
122. Li MJ, Huang CX, Okello E, Yanhong T, Mohamed S. Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Can J Cardiol 2009; 25(9): 523-6.
123. Bernstein M, Tyagi SC. b-Blocker improves cardiac function by reducing oxidative stress and metalloproteinase activity after myocardial infarction. J Appl Res 2001; 1(2).
124. Ohtsuka T, Hamada M, Saeki H, et al. Serum levels of matrix metalloproteinases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. Am J Cardiol 2003; 91(8): 1024-7, A8.
125. Pauschinger M, Rutschow S, Chandrasekharan K, et al. Carvedilol improves left ventricular function in murine coxsackievirusinduced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. Eur J Heart Fail 2005; 7(4): 444-52.
126. Wu TC, Chen YH, Leu HB, et al. Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and-9 in experimental atherosclerosis. Free Radic Biol Med 2007; 43(11): 1508-22.
127. Cimmino G, Ibanez B, Giannarelli C, et al. Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. Int J Cardiol 2011; 153(3): 256-61.
128. Senzaki H, Paolocci N, Gluzband YA, et al. beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ Res 2000; 86(7): 807-15.
129. Song G, Hennessy M, Zhao YL, et al. Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304). Pharmacol Res 2006; 54(1): 57-64.
130. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8(11): 1257-62.
131. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47(4): 648-57.
132. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103(2): 276-83.
133. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003; 23(5): 769-75.
134. Arikan MC, Shapiro SD, Mariani TJ. Induction of macrophage elastase (MMP-12) gene expression by statins. J Cell Physiol 2005; 204(1): 139-45.
135. Yasuda S, Miyazaki S, Kinoshita H, Nagaya N, Kanda M, Goto Y, et al. Enhanced cardiac production of matrix metalloproteinase-2 and-9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Clin Sci (Lond). 2007; 112(1): 43-9.
136. Li J, Zhao SP, Peng DQ, Xu ZM, Zhou HN. Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction. Clin Chem 2004; 50(9): 1696-9.
137. Nakaya R, Uzui H, Shimizu H, et al. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int J Cardiol 2005; 105(1): 67-73.
138. Turner NA, Aley PK, Hall KT, et al. Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and-independent mechanisms. J Mol Cell Cardiol 2007; 43(2): 168-76.
139. Pan M-R, Hung W-C. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 2002; 277(36): 32775-80.
140. Mehta JL, Chen J, Yu F, Li DY. Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res 2004; 64(2): 243-9.
141. Kiran MS, Sameer Kumar VB, Viji RI, Sudhakaran PR. Temporal relationship between MMP production and angiogenic process in HUVECs. Cell Biol Int 2006; 30(9): 704-13.
142. Babine RE, Bender SL. Molecular Recognition of Proteinminus signLigand Complexes: Applications to Drug Design. Chem Rev 1997; 97(5): 1359-472.
143. Hu J, Van den Steen PE, Sang Q-XA, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6(6): 480-98.
144. Shen XH, Chen Q, Shi Y, Li HW. Association of neutrophil/lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J (Engl) 2010; 123(23): 3438-43.
145. Nenan S, Boichot E, Lagente V, Bertrand CP. Macrophage elastase (MMP-12): a pro-inflammatory mediator? Mem Inst Oswaldo Cruz 2005; 100 Suppl 1: 167-72.
146. Klingenberg R, Luscher TF. Inflammation in Coronary Artery Disease and Acute Myocardial Infarction-is the Stage Set for Novel Therapies? Curr Pharm Des 2012; 18(28): 4358-69.
147. Khandoga A, Kessler JS, Hanschen M, et al. Matrix metalloproteinase-9 promotes neutrophil and T cell recruitment and migration in the postischemic liver. J Leukoc Biol 2006; 79(6): 1295-305.
148. Khan HA, Alhomida AS, Sobki SH, Moghairi AA, Koronki HE. Blood cell counts and their correlation with creatine kinase and Creactive protein in patients with acute myocardial infarction. Int J Clin Exp Med 2012; 5(1): 50-5.
149. Granfeldt A, Jiang R, Wang NP, et al. Neutrophil inhibition contributes to cardioprotection by postconditioning. Acta Anaesthesiol Scand 2012; 56(1): 48-56.
150. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999; 277(1): C1-C19.
151. Hinz B, Gabbiani G. Mechanisms of force generation and transmission by myofibroblasts. CurrOpinBiotechnol 2003; 14(5): 538-46.
152. Hinz B. Masters and servants of the force: the role of matrix adhesions in myofibroblast force perception and transmission. Eur J Cell Biol 2006; 85(3-4): 175-81.